Description of Collaborative Activity: |
The CCDI Molecular Targets Platform allows users to browse and identify associations between molecular targets, diseases, and drugs. The RACE Act requires evaluation of new molecularly targeted drugs and biologics intended for the treatment of adult cancers and directed at a molecular target substantially relevant to the growth or progression of a pediatric cancer. This act also eliminates the orphan exemption for pediatric studies of cancer drugs directed at relevant molecular targets. In accordance with the RACE Act, the FDA, in collaboration with NCI and the pediatric cancer research community, developed a Relevant Molecular Target List (RMTL) to provide guidance to industry in planning for new drug and biologic submissions. NCI converted this RMTL list into a computer-readable format with gene-level granularity and all targets mapped and hyperlinked to additional resources and identifiers; integrated this list into Molecular Targets Platform. |
